Biomaterials for 17- OH Progesterone immunoassay development & manufacturing

The determination of circulating levels of 17-OH Progesterone (17-OHP) is a key aid in the diagnosis of medical conditions, such as congenial adrenal hyperplasia (CAH), or to rule out other conditions with similar symptoms. 17-OHP is an endogenous steroid hormone that is an intermediate steroid in the biological pathway to obtain cortisol as well as other steroid compounds from cholesterol^1. 17-OH Progesterone is mainly biosynthesised in the adrenal glands and, to a lesser extent, in the gonads.

In clinical laboratory, the measurement of circulating levels of 17-OH Progesterone is a key aid in the diagnosis of congenial adrenal hyperplasia. CAH is a medical condition characterised by impaired cortisol synthesis due to 21-hydroxylase deficiency, which provokes an increase in the circulating concentration of 17-OHP. The most prominent trait of CAH is the presence of virilising traits in newborn females, and in some cases inadequate aldosterone synthesis, which causes salt wasting that may result in systemic shock^2.  Nowadays, testing of 17-OHP is included in newborn screening programmes for CAH in most developed countries. The estimated incidence of CAH ranges from between 1:14.000 births to 1:18.000 births².

How Werfen can support you

We can support your immunoassay portfolio expansion in the fertility and women’s health panel by providing antibodies for the development and manufacturing of immunoassays to determine 17-OH Progesterone.

Werfen 17-OH Progesterone biomaterials portfolio consist of the following products: